In addition, NSCLC subgroups with higher nodal metastasis levels or cancer stages generally have lower median expression of ABR, PREX1, DOCK2, and DOCK4, whereas statistical significance for the comparison among these subgroups remains to be verified with a larger number of samples. This evidence concerns the gene DOCK4 and cancer.